CAL
PCRX icon

Capital Analysts LLC’s Pacira BioSciences PCRX Stock Holding History

Capital Analysts LLC’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$6K – 793
2020
Q3 		$6K Hold
100
– – ﹤0.01% 641
2020
Q2 		$5K Hold
100
– – ﹤0.01% 610
2020
Q1 		$3K Hold
100
– – ﹤0.01% 622
2019
Q4 		$5K Hold
100
– – ﹤0.01% 618
2019
Q3 		$3K Hold
100
– – ﹤0.01% 640
2019
Q2 		$4K Sell
100
-103
-51% -$4.37K ﹤0.01% 598
2019
Q1 		$7K Hold
203
– – ﹤0.01% 544
2018
Q4 		$9K Hold
203
– – ﹤0.01% 475
2018
Q3 		$10K Buy
+203
New +$8.78K ﹤0.01% 446

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital Analysts LLC's PCRX Position: Q4 2020 in Review

Capital Analysts LLC sold out of Pacira BioSciences (PCRX) in Q4 2020, closing a stake of 100 shares — an estimated $6K sold.

Capital Analysts LLC first reported a position in PCRX in Q3 2018 and held it in 9 quarters. The position peaked at $10K in Q3 2018. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2020.

  • Capital Analysts LLC reported no remaining Pacira BioSciences position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 100 Pacira BioSciences shares in Q4 2020, an estimated $6K.
  • Capital Analysts LLC first reported a position in Pacira BioSciences in Q3 2018 and held it in 9 quarters.
  • Capital Analysts LLC's Pacira BioSciences position peaked at $10K in Q3 2018.
  • 260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.